The results obtained in relation to androstenedione and FSH, after being confirmed in a larger group of postmenopausal women with breast cancer, could represent the basis for stratifying the risk of onset or worsening of frailty under AROi treatment, and may afford a useful biomarker for monitoring intervention strategies in these patients. This evidence concerns the gene BRD2 and breast cancer.